Though adverse effects havent been widely reported, side effects can vary based on individual health
2020 NexGen Pharmaceuticals
D-CuP release from G/D-CuP G/D-CuP was loaded into a dialysis bag (MWCO = 3.5 kDa) and immersed in PBS (pH 7.4) without or with 1 mM H 2 O 2
A 7.5 mg dose at this concentration means injecting 1.5 mL, which is at the upper limit of what most people find comfortable for a subcutaneous injection
some clinicians may start at the lower end (0.2 mg) and adjust based on IGF-1 levels and clinical response
Nothing presented here is intended for human consumption, medical use, veterinary use, diagnosis, treatment, cure, or prevention of disease